Board of Directors

Lisa Evrén

Ms. Evrén is the former Vice President and Treasurer at Talisman-Energy in Calgary, Alberta, Canada, serving from 2010 until 2013. From 2007 until 2010, Ms. Evrén served as the Executive Vice President and Chief Financial Officer of Merrimack Pharmaceuticals, Inc. in Cambridge, Massachusetts, a privately held specialty pharmaceutical company focused on oncology. Prior to Merrimack, Ms. Evrén held roles of increasing responsibility in finance at Amgen Inc. from 2002 until 2007 and at Pfizer Inc. from 1991 until 1997. Ms. Evrén received her BA in Philosophy from Pomona College and her JD and LLM (Taxation) from New York University. Ms. Evrén’s qualifications to serve on the board of directors include her experience as a chief financial officer in the pharmaceutical industry and in the structuring and execution of global capital markets and private funding transactions.

Richard Fante

Richard Fante has served as Chief Commercial Officer and Head of Business Development for Innocoll, Inc. since August 2015 and as President of RF Consulting LLC since April 2013. Prior to founding RF Consulting LLC, Mr. Fante spent more than 19 years at AstraZeneca plc, or AstraZeneca, in the United States. He served in a number of roles, most recently as President of its U.S. business, CEO of North America, and Regional Vice President of the Americas. Prior to assuming his role as President of AstraZeneca U.S. in November 2008, Mr. Fante served as the head of Brand Strategy and Portfolio Operations at AstraZeneca. From January 1992 until December 1994, Mr. Fante worked at Lederle Laboratories, where his roles included sales representative and brand manager. Mr. Fante served as Board Chairman of the National Pharmaceutical Council (2012) and was a member of the Institute of Medicine of the National Academies of Science Roundtable on Value and Science. Mr. Fante received his BA in Biology from Princeton University and his MBA from the University of North Carolina at Chapel Hill. Mr. Fante’s qualifications to serve on the board of directors include his experience as a pharmaceutical executive and his leadership in the development and commercialization of pharmaceutical products.

Hilary M. Malone, Ph.D.

Dr. Malone is an experienced business leader in the pharmaceutical industry with specialist expertise in global regulatory affairs and compliance spanning the development, registration, and marketing of innovative prescription drugs and vaccines. Dr. Malone currently serves as Chief Regulatory Officer and Head of Global Regulatory Affairs for Sanofi, S.A., a position she has held since July 2013. Prior to joining Sanofi, S.A., Dr. Malone served as the Chief Regulatory & Compliance Officer for Reata Pharmaceuticals, a small U.S.-based biotech company from 2011 to 2013. Dr. Malone also held roles as the Senior Vice President and Head of Worldwide Regulatory Strategy for both Wyeth (from 2006 to 2009) and Pfizer Inc., (from 2009 to 2011), overseeing all products across the human health businesses (pharmaceuticals and vaccines, consumer health brands, generics, and infant nutritionals). Earlier in her career, Dr. Malone held positions of increasing responsibility at GlaxoSmithKline plc and its predecessor, SmithKline Beecham plc, from 1993 to 2001 and at AstraZeneca from 2011 to 2006. Dr. Malone earned her B.Sc. in Physiology and her Ph.D. in Molecular Neuropharmacology from the University of Dundee, Scotland, U.K. and also spent time in postdoctoral research at the University of California, San Francisco prior to joining the pharmaceutical industry. Dr. Malone’s qualifications to serve on the board of directors include her experience in global regulatory affairs and compliance spanning the development, registration, marketing, and commercialization of innovative prescription drugs and vaccines.

Peter Mueller, PhD.

has served as the President of the Mueller Health Foundation, a private foundation dedicated to combatting globally lethal infectious diseases such as tuberculosis, since January 2017. Previously, he served as President of R&D and Chief Scientific Officer of Axcella Health from November 2014 until January 2017. From July 2003 to October 2014, Dr. Mueller served as Executive Vice President Global Research and Development & Chief Scientific Officer for Vertex Pharmaceuticals, where he provided strategic oversight for Vertex’s worldwide drug discovery research programs, pharmaceutical development, quality assurance and control, and pharmaceutical operations as well as clinical and nonclinical development, regulatory, patient safety, and medical affairs. Prior to his tenure at Vertex, Dr. Mueller served as Senior Vice President, Research and Development, for Boehringer Ingelheim from April 1997 until June 2003, where he was responsible for the development of all drug candidates of the company’s worldwide portfolio in North and South America, Canada, and Japan. He also led research programs in the areas of immunology, inflammation, cardiovascular disease, and gene therapy on a global basis. During his time at Boehringer Ingelheim, Dr. Mueller oversaw the discovery of numerous development candidates and held several positions in basic research, medicinal chemistry, and management at various locations of Boehringer Ingelheim worldwide.

Dr. Mueller received both his undergraduate degree and his PhD in Chemistry at the Albert Einstein University of Ulm, Germany, where he also received a Professorship in Theoretical Organic Chemistry. He completed fellowships in Quantum Pharmacology at Oxford University and in Biophysics at the University of Rochester.

His special fields of studies include synthetic organic chemistry, computational chemistry (cheminformatics and bioinformatics), RNA-biophysics, atherosclerosis research, IMID (Immune Mediated Inflammatory Diseases), neurodegenerative diseases, infection, oncology, gene/epigenetic technology, artificial intelligence, and management/business strategies (IMD).

He is a member of various scientific and political societies, including the Gesellschaft Deutscher Chemiker (GDCh) and Verband Chemische Industrie (Germany), Royal Society of Chemistry (UK), IRI, RNA-Society, ASAP, AAAS (USA). He currently also serves as the Chairman of the board of directors of BioXcel Therapeutics, Inc. and as a director on the board of the US-India Chamber of Commerce Biotech. He also serves as a chair of the Scientific Advisory Board for BioXcel Corporation, is an advisor to the University Iowa (CBB), and is a faculty member of the GLG Institute. Dr. Mueller served on the Advisor Committee at the Harvard Accelerator Fund and on the Scientific Advisory Board for Keystone Symposia. Before he left Connecticut to join Vertex, Dr. Mueller was also a member of Governor Roland’s Council on Economic Competitiveness and Technology for the State of Connecticut (USA).

Dr. Mueller’s qualifications to serve on the board of directors include his experience as a pharmaceutical executive and his leadership in the development and commercialization of pharmaceutical products.

Milton H. Werner, Ph.D.

Prior to founding Inhibikase, Dr. Werner served as Director of Research at Celtaxsys, Inc., a cell-free immunotherapeutics company. From September 1996 until June 2007, Dr. Werner was a Head of the Laboratory of Molecular Biophysics at The Rockefeller University and departed the University at the rank of Associate Professor. While at The Rockefeller University, Dr. Werner focused on developing more complete understandings of mechanisms of human disease in immunology, oncology, and infectious disease research at the cell-free immunotherapeutics company Celtaxsys in Atlanta, Georgia. At Celtaxsys, Dr. Werner drove the research program from the loss of its technology license to a $20 million pre-money valuation at the opening of the company’s Series B investment round. Celtaxsys explores the role of proteins in controlling immune cell migration. Previous to Celtaxsys, Dr. Werner was an internationally recognized scientist, Associate Professor and Head of Lab at the Rockefeller University. At the Rockefeller, Dr. Werner focused on elucidating mechanisms of human disease in immunology, oncology, and infectious disease.

Dr. Werner is the author or co-author of more than 70 research articles, reviews, and book chapters and has given lectures on his research work on more than 150 occasions throughout the world. He is the recipient of numerous private and public research grants totaling more than $10 million and of several awards, including the Young Investigator Award from the Sidney Kimmel Cancer Foundation, the Research Chair from the Brain Tumor Society, and a $1 million Distinguished Young Scholars in Medical Research award from the W. M. Keck Foundation. Dr. Werner received his PhD in Chemistry from the University of California, Berkeley and his BS in Biochemistry from the University of Southern California, and he trained at the National Institutes of Health before joining the Rockefeller in 1996.

Back to Top